Researchers from the University of California San Diego have developed a low-cost, single-use tattoo-like wearable that measures the user’s glucose levels. According to a release from the institution, this noninvasive technology will be at the center of a newly announced pilot clinical trial designed to test the accuracy and acceptability of the tattoos.
from MobiHealthNews https://ift.tt/2qRjtX8
April 24, 2018
Rose
MobiHealthNews
No comments
Related Posts:
UpToDate Advanced brings interactive decision making to Wolters Kluwer's reference toolNetherlands-based Wolters Kluwer today announced the launch of UpToDate Advanced, a mobile-friendly physician tool that offers interactive guidance through clinical decision-making. The new offering builds on medical informat… Read More
Fitbit Ionic: Adidas edition revealed, promises running-specific trainingWearable giant Fitbit and fitness apparel company Adidas have just released their latest running-specific training wearable, the Fitbit Ionic: Adidas edition. The product was born out of a partnership between the two companie… Read More
HIMSS18 Connected Health Experience to feature AI, voice assistants, and moreThe Personal Connected Health Alliance’s Digital Health Pavilion at HIMSS18 will once again feature “The Connected Health Experience,” a series of presentations and demonstrations of the latest connected health innovations. B… Read More
Boston Children's Hospital uses VR to show young patients their insidesWithout a medical background, listening to a doctor describe a complex procedure can feel a little bit like listening to a lecture in gibberish. That communication gap is particularly wide between pediatric patients and their… Read More
AI hospital logistics platform Tagnos raises $5M from investorsTagnos, maker of an AI-powered logistics platform for hospitals and clinics, announced today that it has raised $5 million in investment funding from Benhamou Global Ventures, Morpheus Ventures, and Zebra Ventures. from Mobi… Read More
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment